Raltegravir central nervous system tolerability in clinical practice: Results from a multicenter observational study

AIDS

Volumn 26, Issue 18, 2012, Pages 2412-2415

  Madeddu, Giordano ^a   Menzaghi, Barbara ^b   Ricci, Elena ^c   Carenzi, Laura ^c   Martinelli, Canio ^d   Di Biagio, Antonio ^e   Parruti, Giustino ^f   Orofino, Giancarlo ^g   Mura, Maria S ^a   Bonfanti, Paolo ^h  

^a UNIVERSITY OF SASSARI   (Italy)

^b BUSTO ARSIZIO HOSPITAL   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d Universitaria Careggi   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f Pescara General Hospital   (Italy)

^g AMEDEO DI SAVOIA HOSPITAL   (Italy)

^h A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; EFAVIRENZ; PROTON PUMP INHIBITOR; RALTEGRAVIR; TENOFOVIR;

ADULT; ANXIETY; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; DEPRESSION; DIZZINESS; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS C; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT; SLEEP DISORDER; SUICIDE ATTEMPT;

ADENINE; ANTI-HIV AGENTS; CENTRAL NERVOUS SYSTEM; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; ORGANOPHOSPHONATES; PYRROLIDINONES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870248698     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835aa141     Document Type: Article

References (23)

1. Lennox JL, De Jesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenzbased combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806.
2. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52:350-356.
3. Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010;50:605-612.
4. Gatell JM, Katlama C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, et al. Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study. J Acquir Immune Defic Syndr 2010;53:456-463.
5. Lataillade M, Kozal MJ. The hunt for HIV-1 integrase inhibitors. AIDS Patient Care STDS 2006;20:489-501. (Pubitemid 44078768)
6. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-650. (Pubitemid 30070911)
7. Cocohoba J, Dong BJ. Raltegravir: the first HIV integrase inhibitor. Clin Ther 2008;30:1747-1765.
8. Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos 2007;35:1657-1663. (Pubitemid 47296061)
9. Merck and Co, Isentress TM Prescribing Information. http://www.merck.com/ product/usa/pi-circulars/i/isentress/isentress-pi.pdf. [Accessed 17 February 2012]
10. Stellbrink HJ. Raltegravir in the management of HIV-infected patients. Drug Des Devel Ther 2009;2:281-288.
11. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009;4:e6877.
12. Gray J, Young B. Acute onset insomnia associated with the initiation of raltegravir: a report of two cases and literature review. AIDS Patient Care STDS 2009;23:689-690.
13. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases. AIDS 2008;22:1890-1892.
14. Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, et al. An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir. J Acquir Immune Defic Syndr 2005;39:317-320. (Pubitemid 40923212)
15. Wenning LA, Friedman EJ, Kost JT, Breidinger SA, Stek JE, Lasseter KC, et al. Lack of a significant interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 2008;52:3253-3258.
16. Iwamoto M, Wenning LA, Nguyen B-Y, Teppler H, Moreau AR, Rhodes RR, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009;48:489-492.
17. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001;15:71-75. (Pubitemid 32055781)
18. Fayet Mello A, Buclin T, Decosterd LA, Delhumeau C, di Iulio J, Fleurent A, et al. Successful efavirenz dose reduction guided by therapeutic drug monitoring. Antivir Ther 2011;16:189-197.
19. Cattaneo D, Gervasoni C, Meraviglia P, Landonio S, Fucile S, Cozzi V, et al. Inter and intra-patient variability of raltegravir pharmacokinetics in HIV-1 infected subjects. J Antimicrob Chemother 2012;67:460-464.
20. Arab-Alameddine M, Fayet-Mello A, Lubomirov R, Neely M, di Iulio J, Owen A, et al. Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals. Antimicrob Agents Chemother 2012;56:2959-2966.
21. Eiden C, Peyriere H, Peytavin G, Reynes J. Severe insomnia related to high concentrations of raltegravir. AIDS 2011;25:725-727.
22. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S, Clifford D, et al., for the CHARTER Group. Total raltegravir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010;54:5156-5160.
23. Calcagno A, Bonora S, Bertucci R, Lucchini A, D'Avolio A, Di Perri G. Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. AIDS 2010;24:931-932.